The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia
Open Access
- 15 September 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 128 (11), 1525-1528
- https://doi.org/10.1182/blood-2016-02-699439
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaNew England Journal of Medicine, 2013
- Arsenic exposure in Latin America: Biomarkers, risk assessments and related health effectsScience of The Total Environment, 2011
- Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupBlood, 2010
- Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort studyThe Lancet, 2010
- High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGLeukemia, 2009
- Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 2009
- Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradationNature Medicine, 2008
- All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 2004
- Ingested Arsenic and Internal Cancer: A Historical Cohort Study Followed for 33 YearsAmerican Journal of Epidemiology, 1995
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993